Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.
A rock around the KRAS clock
First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22
5 key and novel early areas of development which stood out to us at AACR22
What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?
Hot or not - 5 early stage trials with different agents and targets
5 abstracts to watch out for at the ASCO22 meeting in Chicago
New CAR-T cell developments in solid tumours - hit or miss?
Looking beyond the hype from a broader perspective
Highlights from the KRAS front with three different company products not named sotorasib or adagrasib
Going beyond both G12C and G12D to a plethora of new targets and combination approaches
All aboard to hear more about novel targeted therapy combination strategies...
Finding new synthetic lethal targets to induce more potent cell death and improve outcomes
Everything you needed to know about bispecifics at AACR22 and more!
What to watch out for at AACR22 if you're interested in NK cells
5 areas to watch out for on the bispecific antibody front
Just because a pathway has been called undruggable doesn't always mean it will be so!
Hot topics to follow at AACR22
